ross margin anticipated to
exceed 40 percent and that operating expenses will be relatively comparable
with fiscal 2008. As a result, management expects to exit the fourth fiscal
quarter at break even.
Conference call details:
Dial-in (U.S.): 1-800-860-2442
Dial-in (International): 412-858-4600
Conference name: "ThermoGenesis"
To listen to the audio webcast of the call during or after the event,
please visit:
http://www.thermogenesis.com/investors-webcasts-and-calls.aspx.
An audio replay of the conference call will be available beginning
approximately two hours after completion of the call for the following five
business days.
To access the replay:
Access number (U.S.): 1-877-344-7529
Access number (International): 412-317-0088
Conference ID#: 385107
THERMOGENESIS CORP.
Condensed Consolidated Balance Sheets
(Unaudited)
June 30, June 30,
2008 2007
ASSETS
Current assets:
Cash and cash equivalents $4,384,000 $5,730,000
Short term investments 20,903,000 27,649,000
Accounts receivable, net 5,976,000 3,226,000
Inventory 5,131,000 5,046,000
Other current assets 367,000 415,000
Total current assets 36,761,000 42,066,000
Equipment, net 1,450,000 1,602,000
Other assets 71,000 122,000
'/>"/>
SOURCE ThermoGenesis Corp. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 Related biology technology :1.
ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 20072.
ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results3.
ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 20074.
ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 20075.
ThermoGenesis Corp. to Announce Second Quarter Fiscal 2008 Results on February 6, 20086.
ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year7.
ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets8.
ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health9.
ThermoGenesis Names Dr. Mahendra Rao to Board of Directors10.
ThermoGenesis Announces Receipt of CE Mark for MarrowXpress(TM)11.
ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM))